- Oudaha, Khalid
- Arcas, José Miguel
- Peña, Elvira de la
- Sala, Salvador
- Viana, Félix
Resumen del póster presentado al International Workshop on Chronic Pain and Itch: Mechanisms and Circuits, celebrado en Alicante (España) del 20 al 22 de octubre de 2021., Transient Receptor Potential Melastatin 8 (TRPM8), is a polymodal non-selective cation channel activated by cold temperature, cooling compounds (e.g. menthol) and voltage. TRPM8 is expressed in primary sensory neurons and their peripheral nerve terminals. TRPM8 plays crucial physiological roles in environmental cold sensing and thermoregulation. It is also involved in pathophysiological conditions like cold hypersensitivity in painful neuropathies, migraine and dry eye disease. On the other hand, activation of TRPM8-expressing fibers by cold or menthol has analgesic and antipruritic effects. This functional profile makes TRPM8 a prime channel for development of novel pain modulators. Previously, we identified the immunosuppressant macrolide Tacrolimus (FK506) as a specific activator of TRPM8 channels in recombinant and native systems (Arcas et al., 2019). Here, we explored the actions of Rapamycin (Sirolimus), a structurally analogous macrolide molecule, characterised by inhibition of mTOR, a kinase regulating different cellular processes. Tacrolimus is widely used clinically as an immunosuppressant to prevent tissue rejection following organ transplantation. Combining in vitro calcium imaging and patch-clamp recordings, we found that Rapamycin activates TRPM8 channels from different species, including humans, expressed heterologously in a HEK293 cell line. Furthermore, Rapamycin activated large whole-cell currents in HEK293 cells expressing mouse TRPM8. The current-voltage relationship of Rapamycin-activated current showed strong outward rectification and a reversal potential close to 0 mV, in line with the previously described characteristics of TRPM8 channels (Voets et al,.2004). Cold-evoked inward and outward currents, measured at -100 mV and +100mV respectively, were strongly potentiated in the presence of Rapamycin. Additionally, Rapamycin caused a strong shift of V1/2 for channel activation towards more negative membrane potentials. The selective TRPM8 antagonist AMTB completely suppressed Rapamycin-evoked currents whereas it partially inhibits cold response in the presence of Rapamycin. In cold-sensitive TRPM8-expressing DRG neurons, Rapamycin selectively activated inward currents, strongly potentiated their cold evoked response and increased the firing frequency during cold stimulation. Finally, in order to understand the interactions of Rapamycin with TRPM8, we examined the effects of single point mutations on different segments, including S1, S4 and TRP domains. In conclusion, our results identified TRPM8 as a novel molecular target of the clinically approved drug Rapamycin., Supported by Ministerio de Ciencia e Innovación, PID2019-108194RB-100 co-financed by the European Regional Development Fund (ERDF), the “Severo Ochoa” Program for Centers of Excellence in R&D SEV-2017-0723 and predoctoral fellowships GRISOLIA/2019/089., Peer reviewed